BMC Cancer. 2013 May 4;13:226. doi: 10.1186/1471-2407-13-226.
The prognostic value of gender and age in the survival of nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT) is unclear. Several studies have suggested a female advantage in the prognosis of solid tumors. We investigated the relationship between gender differences and disease outcome in NPC patients treated with IMRT in South China.
A total of 299 patients with non-disseminated NPC were analyzed retrospectively. IMRT was delivered with a simultaneous modulated, accelerated radiotherapy boost technique at prescribed doses of 70 Gy/30 fractions/6 weeks to the primary tumor (GTVp) and positive neck nodes (GTVn), 60Gy (2.0 Gy/day) to the clinical target volume (CTV) and upper neck region and 54 Gy (1.8 Gy/day) to the clinically negative low neck. A median boost dose of 9.2 Gy (4-20 Gy) was administered to patients with persistent disease at the primary site.
With a median follow-up of 52 months, the male patients had a significantly unfavorable 5-year OS (70.7% compared to 94.1%, P < 0.001), DPFS (71.5% compared to 87.3%, P = 0.029) and DMFS (77.2% compared to 89.7%, P = 0.036) than the female patients. In patients younger than 45, the male patients had a poorer 5-year OS (66.8% compared to 91.2%, P = 0.008), DPFS (59.9% compared to 91.2%, P = 0.005) and DMFS (66.4% compared to 94.0%, P = 0.004) than the female patients. For patients older than 45, only the 5-year OS (72.2% compared to 96.0%, P = 0.001) was significantly different.
Gender and age are strong independent prognostic factors for NPC in this study. We are the first to report that younger male patients were more likely to have distant metastases and exhibited inferior overall survival and disease progression-free survival rates compared to other patients.
在接受调强放疗(IMRT)治疗的鼻咽癌(NPC)患者中,性别和年龄对生存的预后价值尚不清楚。一些研究表明,女性在实体瘤的预后方面具有优势。我们研究了华南地区接受 IMRT 治疗的 NPC 患者中性别差异与疾病结局的关系。
回顾性分析了 299 例非转移性 NPC 患者。采用同步调强加速放疗推量技术,对原发肿瘤(GTVp)和阳性颈部淋巴结(GTVn)给予 70Gy/30 次/6 周,对临床靶区(CTV)和颈部上区给予 60Gy(2.0Gy/天),对临床阴性低颈部给予 54Gy(1.8Gy/天)。对原发部位持续性疾病患者给予中位数为 9.2Gy(4-20Gy)的中位推量剂量。
中位随访 52 个月后,男性患者的 5 年 OS(70.7%比 94.1%,P<0.001)、DPFS(71.5%比 87.3%,P=0.029)和 DMFS(77.2%比 89.7%,P=0.036)显著低于女性患者。在年龄小于 45 岁的患者中,男性患者的 5 年 OS(66.8%比 91.2%,P=0.008)、DPFS(59.9%比 91.2%,P=0.005)和 DMFS(66.4%比 94.0%,P=0.004)显著低于女性患者。对于年龄大于 45 岁的患者,只有 5 年 OS(72.2%比 96.0%,P=0.001)有显著差异。
在这项研究中,性别和年龄是 NPC 的两个强有力的独立预后因素。我们首次报道,年轻的男性患者更有可能发生远处转移,与其他患者相比,总生存和疾病无进展生存率较低。